Sevoflurane in Electroconvulsive Therapy
Information source: Inonu University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: ECT; Anesthesia
Intervention: sevorane (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Inonu University Official(s) and/or principal investigator(s): Huseyin Toprak, Professor, Principal Investigator, Affiliation: Inonu University
Summary
The purpose of the study was to investigate the effects of different doses of sevoflurane
used in electroconvulsive therapy (ECT) on duration of seizure, hemodynamic response and
recovery profiles
Clinical Details
Official title: The Comparision of Different Doses of Sevoflurane for Induction of General Anesthesia in Electroconvulsive Therapy
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: sevoflurane used in electroconvulsive therapy (ECT) on duration of seizure
Secondary outcome: sevoflurane used in electroconvulsive therapy (ECT) on hemodynamic response.
Detailed description:
Motor (EMG) and electroencephalography seizure duration (EEG), heart rate (HR) and mean
arterial pressure (MAP) values, and recovery times were recorded.
Eligibility
Minimum age: 18 Years.
Maximum age: 60 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Study included 25 patients of American Society of Anesthesiologists (ASA) physical
status I-II aged between 18-60 years who were scheduled for ECT sessions under
general anesthesia
Exclusion Criteria:
- Pregnancy
- Cerebrovascular disease
- Epilepsy
- Unstable cardiovascular disease
- Chronic obstructive pulmonary disease; and
- Renal or hepatic failure
Locations and Contacts
Inonu Unıversity School of Medicine, Malatya 44100, Turkey
Additional Information
Starting date: March 2013
Last updated: July 22, 2013
|